Zuckerman Investment Group Acquires $3.4M Stake in Harmony Biosciences

The investment firm takes a 0.21% position in the biopharmaceutical company.

Mar. 14, 2026 at 11:30am

Got story updates? Submit your updates here. ›

Zuckerman Investment Group LLC acquired a new stake of 123,255 shares in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the third quarter, valued at approximately $3.4 million. This represents a 0.21% ownership stake in the biopharmaceutical company, which focuses on developing therapies for rare neurological and endocrine diseases.

Why it matters

Harmony Biosciences is a relatively new public company, having gone public in 2020, so this investment by Zuckerman Investment Group signals confidence in the company's growth potential and product pipeline. The acquisition also represents a sizable stake for the investment firm in the $1.6 billion market cap company.

The details

According to a 13F filing with the SEC, Zuckerman Investment Group acquired the 123,255 shares of Harmony Biosciences in the third quarter. This gives the investment firm approximately 0.21% ownership in the company. Harmony Biosciences' flagship product is WAKIX, the first and only histamine H3 receptor antagonist/inverse agonist approved by the FDA for the treatment of narcolepsy.

  • Zuckerman Investment Group acquired the Harmony Biosciences stake in the third quarter of 2026.

The players

Zuckerman Investment Group LLC

An investment firm that acquired a new stake in Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc.

A commercial-stage biopharmaceutical company focused on developing therapies for rare neurological and endocrine diseases.

Got photos? Submit your photos here. ›

The takeaway

This investment by Zuckerman Investment Group underscores the growth potential that institutional investors see in Harmony Biosciences and its lead product WAKIX. As a relatively new public company, this sizable stake acquisition signals confidence in Harmony's ability to continue expanding its rare disease portfolio and driving shareholder value.